140 related articles for article (PubMed ID: 8915751)
21. Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents.
Siedek F; Muehe AM; Theruvath AJ; Avedian R; Pribnow A; Spunt SL; Liang T; Farrell C; Daldrup-Link HE
Eur Radiol; 2020 Mar; 30(3):1790-1803. PubMed ID: 31844962
[TBL] [Abstract][Full Text] [Related]
22. In Vivo Experimental Study of an Endoscopic Ultrasound Multifunctional Radiofrequency Ablation Probe.
Ungureanu BS; Dumitrascu SI; Margaritescu C; Pirici D; Gheonea IA; Sandulescu L; Tudorache S; Tudorache S; Tica OS; Sandru V; Saftoiu A
Curr Health Sci J; 2016; 42(4):359-364. PubMed ID: 30581590
[TBL] [Abstract][Full Text] [Related]
23. Biosafety evaluation of Janus Fe
Su H; Song X; Li J; Iqbal MZ; Kenston SSF; Li Z; Wu A; Ding M; Zhao J
Int J Nanomedicine; 2018; 13():6987-7001. PubMed ID: 30464454
[TBL] [Abstract][Full Text] [Related]
24. Ten Things You Might Not Know about Iron Oxide Nanoparticles.
Daldrup-Link HE
Radiology; 2017 Sep; 284(3):616-629. PubMed ID: 28825888
[TBL] [Abstract][Full Text] [Related]
25. Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy.
Zhu L; Zhou Z; Mao H; Yang L
Nanomedicine (Lond); 2017 Jan; 12(1):73-87. PubMed ID: 27876448
[TBL] [Abstract][Full Text] [Related]
26. Imaging of focal nodular hyperplastic-like nodules in alcoholic liver cirrhosis patients using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid magnetic resonance imaging.
Miyaaki H; Ichikawa T; Taura N; Miuma S; Kawaguchi M; Kohno R; Isomoto H; Takeshima F; Nakashima O; Nakao K
Clin J Gastroenterol; 2011 Aug; 4(4):266-272. PubMed ID: 26189532
[TBL] [Abstract][Full Text] [Related]
27. Biodistribution of newly synthesized PHEA-based polymer-coated SPION in Sprague Dawley rats as magnetic resonance contrast agent.
Park J; Cho W; Park HJ; Cha KH; Ha DC; Choi YW; Lee HY; Cho SH; Hwang SJ
Int J Nanomedicine; 2013; 8():4077-89. PubMed ID: 24204138
[TBL] [Abstract][Full Text] [Related]
28. The effects of iron oxide incorporation on the chondrogenic potential of three human cell types.
Saha S; Yang XB; Tanner S; Curran S; Wood D; Kirkham J
J Tissue Eng Regen Med; 2013 Jun; 7(6):461-9. PubMed ID: 22396122
[TBL] [Abstract][Full Text] [Related]
29. Molecular imaging of tumor invasion and metastases: the role of MRI.
McCann TE; Kosaka N; Turkbey B; Mitsunaga M; Choyke PL; Kobayashi H
NMR Biomed; 2011 Jul; 24(6):561-8. PubMed ID: 21793070
[TBL] [Abstract][Full Text] [Related]
30. Magnetic resonance imaging of the liver: New imaging strategies for evaluating focal liver lesions.
Coenegrachts K
World J Radiol; 2009 Dec; 1(1):72-85. PubMed ID: 21160723
[TBL] [Abstract][Full Text] [Related]
31. Functional investigations on human mesenchymal stem cells exposed to magnetic fields and labeled with clinically approved iron nanoparticles.
Schäfer R; Bantleon R; Kehlbach R; Siegel G; Wiskirchen J; Wolburg H; Kluba T; Eibofner F; Northoff H; Claussen CD; Schlemmer HP
BMC Cell Biol; 2010 Apr; 11():22. PubMed ID: 20370915
[TBL] [Abstract][Full Text] [Related]
32. Surgical therapy for colorectal metastases to the liver.
Pawlik TM; Choti MA
J Gastrointest Surg; 2007 Aug; 11(8):1057-77. PubMed ID: 17530336
[TBL] [Abstract][Full Text] [Related]
33. [MRT of the liver. Clinical significance of nonspecific and liver-specific MRT contrast agents].
Ba-Ssalamah A; Happel B; Kettenbach J; Dirisamer A; Wrba F; Längle F; Schima W
Radiologe; 2004 Dec; 44(12):1170-84. PubMed ID: 15551031
[TBL] [Abstract][Full Text] [Related]
34. [Dynamic and static MRI using superparamagnetic MRI contrast medium Resovist for visualizing primary and secondary liver tumors].
Vogl TJ; Schwarz W; Hammerstingl R; Kümmel S; Balzer JO; Mack MG; Diebold T; Balzer T; Shamsi K; Bechstein WO; Schrem H; Neuhaus P; Felix R
Rofo; 1997 Sep; 167(3):264-73. PubMed ID: 9376555
[TBL] [Abstract][Full Text] [Related]
35. Superparamagnetic iron oxide--enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions.
Vogl TJ; Hammerstingl R; Schwarz W; Mack MG; Müller PK; Pegios W; Keck H; Eibl-Eibesfeldt A; Hoelzl J; Woessmer B; Bergman C; Felix R
Radiology; 1996 Mar; 198(3):881-7. PubMed ID: 8628887
[TBL] [Abstract][Full Text] [Related]
36. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
[TBL] [Abstract][Full Text] [Related]
37. Eovist Injection and Resovist Injection: two new liver-specific contrast agents for MRI.
Mintorovitch J; Shamsi K
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 3):37-40. PubMed ID: 10887650
[TBL] [Abstract][Full Text] [Related]
38. Hepatic MRI with SPIO: detection and characterization of focal liver lesions.
Reimer P; Tombach B
Eur Radiol; 1998; 8(7):1198-204. PubMed ID: 9724439
[TBL] [Abstract][Full Text] [Related]
39. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
